Carregant...
Tripeptide tyroserleutide plus doxorubicin: therapeutic synergy and side effect attenuation
BACKGROUND: Tripeptide tyroserleutide (YSL) is a novel small molecule anti-tumor polypeptide that has been shown to inhibit the growth of human liver cancer cells. In this study, we investigated the effects of YSL plus doxorubicin on the growth of human hepatocellular carcinoma BEL-7402 cells that h...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2008
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2601048/ https://ncbi.nlm.nih.gov/pubmed/19025669 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-8-342 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|